Detail akcie Aptose Bio Rg online

Business Summary: Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aptose Biosciences Inc revenues was not reported. Net loss decreased 26% to $17.7M. Lower net loss reflects Research and development - Balancing val decrease of 50% to $5.4M (expense), Personnel expenses decrease of 47% to $2.3M (expense), Stock-based compensation decrease of 63% to $251K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$46.24 to -$7.37.